Open Orphan’s hVIVO launches its Disease in Motion platform

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in Motion® platform. This unique data-focused platform includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has multiple infectious disease applications that are applicable to a wide variety of end users including big tech, wearables, pharma and biotech companies.

hVIVO has been at the forefront of running human challenge studies for more than 20 years and has built up one of the most comprehensive, multi-parametric bio and databanks ever created for infectious diseases. This dataset from the Disease in Motion platform is continuously gathered throughout the onset, progression and resolution of an infection which is enabled by hVIVO’s challenge study model. The Company is committed to volunteer patient data privacy and data is only collected from fully consented volunteers in accordance with all relevant privacy guidelines. 

For more information on the platform, please visit www.hvivo.com/DiseaseInMotion  

Cathal Friel, Executive Chairman said: “The Disease in Motion platform includes data from cutting edge wearables that are applicable to a wide variety of end users including big tech, wearables, pharma and biotech companies. As volunteers remain under close observation prior to viral challenge, during disease progression and until resolution, data is captured across the full time-course of the infection, yielding possible insights into the body’s response to infection. The Disease in Motion platform currently spans several conditions with plans to expand this going forward.  

As a recognised global leader in supporting the development of therapeutics and vaccines, hVIVO and our team of virological, clinical and regulatory experts are actively in discussion with potential partners to help address the next set of challenges facing humanity.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

CMC regulatory team capabilities

For 20+ years, members of the CMC regulatory team supported several (bio)pharmaceutical companies to ensure manufacture of safe, effective, and high-quality drug products for patients globally. The support includes: Independent, trusted advice on your regulatory activities

Open Orphan Plc

How to build up your child’s immune system

Our Top 7 Tips to Boots Your Child’s Immune System Protecting your children from germs, bacteria and illnesses is a common concern for parents. Flu, colds, viruses and infections can cause misery for both you and

Open Orphan Plc

Open Orphan’s hVIVO presenting at the World Vaccine Congress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a

Open Orphan Plc

Hay fever season is back with a vengeance

Hay Fever is back! As the most common form of non-infectious rhinitis, hay fever affects 10-30% of adults and up to 40% of children. Hay fever season typically starts in mid-March as trees bloom until May.

Open Orphan Plc

Open Orphan Investor Presentation March 2022 (Video)

Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation. Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and

Open Orphan Plc

Strategies for Non-clinical safety assessment of vaccines

Setting the scene Over the past century, vaccines have made a large impact on public health, as recently demonstrated by the treatment of the worldwide Covid-pandemic. Since, in general, vaccines are administered to healthy individuals, including

Open Orphan Plc

Open Orphan’s hVIVO signs €6m contract for respiratory study

Dublin-listed clinical trials group Open Orphan has announced that its subsidiary Hvivo has signed a £5 million (€6m) human challenge study contract with a European biotechnology company. The study will test the company’s intravenous antiviral candidate for respiratory syncytial virus,

Open Orphan Plc

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester. Open Orphan tests vaccines and antivirals using human

Open Orphan Plc

FluCamps’ UK Covid Challenge summary

FluCamps’ parent company hVIVO recently published results for the world’s first COVID-19 human challenge trial, World’s first COVID-19 Characterisation Study (investis.com), which ran in Spring of 2021. FluCamp recruited 36 volunteers for this trial under the title

Open Orphan Plc

Clinical PK and PD Service at Venn Breda

For more than 20 years, the clinical pharmacokinetic (PK: understanding the kinetics of a drug in terms of absorption, distribution, metabolism and elimination [ADME]) and pharmacodynamic (PD: the biochemical and physiological effects of a drug) team

Open Orphan Plc

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin ‘Mo’ Khan as its chief executive with immediate effect. Mr Khan joined the company’s board as a non-executive director in October 2021 and has worked